Vertex Buys Alpine Immune Sciences and its Kidney Disease Drug for US$4.9 B
By Lucy Haggerty
Pharma Deals Review: Vol 2024 Issue 4 (Table of Contents)
Published: 17 Apr-2024
DOI: 10.3833/pdr.v2024.i4.2870 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Vertex Pharmaceuticals has entered into an agreement to acquire clinical stage biotech, Alpine Immune Sciences, for US$65 per share or approximately US$4...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS